Societal CDMO (SCTL) 10-Q 7 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 05, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	REPH
Entity Registrant Name	Recro Pharma, Inc.
Entity Central Index Key	1,588,972
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		21,477,498

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 35,788	$ 60,984
Short-term investments	1,243	3,498
Accounts receivable	11,745	9,686
Contract asset	7,465
Inventory	10,182	9,839
Prepaid expenses and other current assets	3,274	3,276
Total current assets	69,697	87,283
Property, plant and equipment, net	41,528	39,074
Deferred income taxes	25,066	18,573
Intangible assets, net	32,912	34,850
Goodwill	6,446	6,446
Total assets	175,649	186,226
Current liabilities:
Accounts payable	4,888	7,954
Accrued expenses and other current liabilities	12,295	9,897
Current portion of contingent consideration	33,957	32,053
Total current liabilities	51,140	49,904
Long-term debt, net	54,675	53,598
Warrants and other long-term liabilities	801	3,516
Long-term portion of contingent consideration	55,486	50,360
Total liabilities	162,102	157,378
Commitments and contingencies (Note 13)
Shareholders’ equity:
Preferred stock, $0.01 par value. Authorized, 10,000,000 shares; none issued and outstanding
Common stock, $0.01 par value. Authorized, 50,000,000 shares; issued and outstanding, 20,727,498 shares at September 30, 2018 and 19,127,435 shares at December 31, 2017	207	191
Additional paid-in capital	160,296	140,006
Accumulated deficit	(146,956)	(111,348)
Accumulated other comprehensive loss		(1)
Total shareholders’ equity	13,547	28,848
Total liabilities and shareholders’ equity	$ 175,649	$ 186,226

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	20,727,498	19,127,435
Common stock, shares outstanding	20,727,498	19,127,435

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 18,283	$ 17,114	$ 59,564	$ 52,790
Operating expenses:
Cost of sales (excluding amortization of intangible assets)	8,472	6,882	31,033	27,829
Research and development	11,348	9,296	29,947	24,132
General and administrative	6,969	6,635	29,442	16,990
Amortization of intangible assets	646	646	1,938	1,937
Change in warrant valuation	287	808	(78)	15
Change in contingent consideration valuation	4,115	3,550	7,030	9,323
Total operating expenses	31,837	27,817	99,312	80,226
Operating loss	(13,554)	(10,703)	(39,748)	(27,436)
Other income (expense):
Interest income	126	62	382	284
Interest expense	(2,198)	(1,235)	(6,490)	(3,625)
Net loss before income taxes	(15,626)	(11,876)	(45,856)	(30,777)
Income tax benefit	2,370	2,821	7,430	4,780
Net loss	$ (13,256)	$ (9,055)	$ (38,426)	$ (25,997)
Per share information:
Net loss per share of common stock, basic and diluted	$ (0.64)	$ (0.48)	$ (1.91)	$ (1.36)
Weighted average common shares outstanding, basic and diluted	20,721,330	19,058,956	20,122,569	19,053,636
Net loss	$ (13,256)	$ (9,055)	$ (38,426)	$ (25,997)
Other comprehensive loss:
Unrealized gain/(loss) on available-for-sale securities		68	1	(8)
Comprehensive loss	$ (13,256)	$ (8,987)	$ (38,425)	$ (26,005)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2017	$ 28,848	$ 191	$ 140,006	$ (111,348)	$ (1)
Balance, Shares at Dec. 31, 2017		19,127,435
Stock-based compensation expense	5,250		5,250
Stock option exercise	$ 1,058	$ 2	1,056
Stock option exercise, Shares	179,562	179,562
Issuance of restricted stock units, net of shares withheld for income taxes	$ (91)	$ 1	(92)
Issuance of restricted stock units, net of shares withheld for income taxes, Shares		122,746
Sale of common stock under equity facility, net of transaction costs	11,500	$ 11	11,489
Sale of common stock under equity facility, net of transaction costs, Shares		1,083,040
Cashless exercise of warrants	2,589	$ 2	2,587
Cashless exercise of warrants, Shares		214,715
Change in other comprehensive loss	1				$ 1
Net loss	(38,426)			(38,426)
Cumulative effect of adoption of new accounting standards, net of tax	2,818			2,818
Balance at Sep. 30, 2018	$ 13,547	$ 207	$ 160,296	$ (146,956)
Balance, Shares at Sep. 30, 2018		20,727,498

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (38,426)	$ (25,997)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	5,250	4,265
Non-cash interest expense	968	612
Depreciation expense	3,819	3,655
Amortization	1,938	1,937
Acquired in-process research and development charges		766
Change in warrant valuation	(78)	15
Change in contingent consideration valuation	7,030	9,323
Deferred income taxes	(7,430)	(4,698)
Changes in operating assets and liabilities:
Inventory	(343)	(1,146)
Contract asset	(3,710)
Prepaid expenses and other current assets	170	(1,667)
Accounts receivable	(2,059)	(2,715)
Accounts payable, accrued expenses and other liabilities	(2,192)	(2,391)
Net cash used in operating activities	(35,063)	(18,041)
Cash flows from investing activities:
Purchase of property and equipment	(4,363)	(4,586)
Purchase of short-term investments	(6,225)	(55,626)
Proceeds from maturity of investments	8,500	26,000
Acquisition of license agreement	(82)	(437)
Net cash used in investing activities	(2,170)	(34,649)
Cash flows from financing activities:
Payment of deferred financing costs	(261)
Proceeds from sale of common stock, net of transaction costs	11,331
Payments of withholdings on shares withheld for income taxes	(91)	(17)
Proceeds from option exercise	1,058	27
Net cash provided by financing activities	12,037	10
Net decrease in cash and cash equivalents	(25,196)	(52,680)
Cash and cash equivalents, beginning of period	60,984	64,483
Cash and cash equivalents, end of period	35,788	11,803
Supplemental disclosure of cash flow information:
Cash paid for interest	6,214	3,122
Cash paid for taxes		467
Purchase of property, plant and equipment included in accrued expenses and accounts payable	3,185	774
Withholdings on shares withheld for income taxes included in accrued expenses		233
Retirement of fully depreciated property, plant and equipment	30	$ 152
Common stock issued in connection with equity facility	$ 357

Background

Background	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background	(1) Background Recro Pharma, Inc., or the Company, was incorporated in Pennsylvania on November 15, 2007. The Company is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating contract development and manufacturing, or CDMO division. Each of these divisions are deemed to be reportable segments (see Note 3(m) and Note 17). The Acute Care division is primarily focused on developing innovative products for hospital and other acute care settings, and the CDMO division leverages the Company’s formulation expertise to develop and manufacture pharmaceutical products using the Company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. On April 10, 2015, the Company acquired from Alkermes plc, or Alkermes, worldwide rights to intravenous and intramuscular, or injectable, meloxicam, a proprietary long-acting preferential COX-2 inhibitor being developed for the management of moderate to severe pain, as well as a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia. The acquisition is referred to herein as the Gainesville Transaction. In July 2017, the Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or the FDA, for its lead investigational product candidate intravenous, or IV, meloxicam 30 mg for the management of moderate to severe pain. In May 2018, the Company received a Complete Response Letter, or CRL, from the FDA regarding its NDA for IV meloxicam. In July 2018, the Company participated in a Type A End-of-Review meeting with the FDA to discuss the topics covered in the CRL. Upon receipt and review of the meeting minutes, the Company resubmitted the NDA for IV meloxicam in September 2018. The FDA has set a date for decision on the NDA under the Prescription Drug User Fee Act, or PDUFA, of March 24, 2019.

Development-Stage Risks and Liq

Development-Stage Risks and Liquidity	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Development-Stage Risks and Liquidity	(2) Development-Stage Risks and Liquidity The Company has incurred losses from operations since inception and has an accumulated deficit of $146,956 as of September 30, 2018. Though its CDMO segment has been profitable, the Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its products currently in development. Additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates, including the payment of the Gainesville Transaction contingent payments, which may become due upon achievement of certain development and commercialization milestones for meloxicam (see Note 4). Insufficient funds may cause the Company to delay, reduce the scope of or eliminate one or more of its development, commercialization or expansion activities. The Company may raise such funds through debt refinancing, bank or other loans, sale of assets, through strategic research and development, licensing (including out-licensing) and/or marketing arrangements or through public or private sales of equity or debt securities from time to time. Financing may not be available on acceptable terms, or at all, and failure to raise capital when needed could materially adversely impact the Company’s growth plans and its financial condition or results of operations. Additional debt or equity financing, if available, may be dilutive to the holders of its common stock and may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate its business. The Company’s future operations are highly dependent on a combination of factors, including (i) the continued profitability of the CDMO segment; (ii) the timely and successful completion of additional financing and/or alternative sources of capital, debt, partnering or out-licensing transactions; (iii) the success of its research and development, including the results and timing of its clinical trials; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company’s proposed future products, including IV meloxicam. Management believes that it is probable that the Company will be able to meet its obligations as they become due within one year after the date of the financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Principles	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	(3) Summary of Significant Accounting Principles (a) Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of Form 10-Q and Article 10 of Regulation S-X and, therefore, do not include all of the information and notes required by U.S. GAAP for complete annual financial statements. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2018. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. (b) Use of Estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. (c) Cash and Cash Equivalents Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value because of the changes in interest rates. (d) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture and office equipment; six to ten or more years for manufacturing equipment; two to five years for vehicles; 35 to 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. (e) Business Combinations In accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805, “Business Combinations,” or ASC 805, the Company allocates the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make significant estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from management of the acquired companies and expectations of future cash flows. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. In-process research and development, or IPR&D, is the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D requires the Company to make significant estimates. In a business combination, the Company capitalizes IPR&D as an intangible asset, and for an asset acquisition the Company expenses IPR&D in the Consolidated Statements of Operations and Comprehensive Loss on the acquisition date. (f) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a two-step method for determining impairment. The first step compares a reporting unit’s fair value to its carrying amount to identify potential goodwill impairment. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the second step of the impairment test must be completed to measure the amount of the reporting unit’s goodwill impairment loss, if any. Step two requires an assignment of the reporting unit’s fair value to the reporting unit’s assets and liabilities to determine the implied fair value of the reporting unit’s goodwill. The implied fair value of the reporting unit’s goodwill is then compared with the carrying amount of the reporting unit’s goodwill to determine the goodwill impairment loss to be recognized, if any. Intangible assets include the Company’s royalties and contract manufacturing relationships intangible asset as well as an IPR&D asset. The royalties and contract manufacturing relationships intangible asset is considered a definite-lived intangible asset and is amortized on a straight-line basis over a useful life of six years. Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its Consolidated Statements of Operations and Comprehensive Loss. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test, which compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. Based on accounting standards, it is required that these assets be assessed at least annually for impairment unless a triggering event occurs between annual assessments, which would then require an assessment in the period which a triggering event occurred. The Company performs its annual goodwill and indefinite-lived intangible asset impairment test as of November 30 th (g) Revenue Recognition The Company generates revenues from manufacturing, packaging, research and development, and related services for multiple pharmaceutical companies through its CDMO segment. The agreements that the Company has with its commercial partners provide for manufacturing revenues, sales-based royalties and/or profit sharing components. The Company’s revenue policies listed below are reflective of Accounting Standards Update, or ASU, No. 2014-09, “ Revenue from Contracts with Customers,” Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include pricing and volume-based adjustments. In addition to manufacturing and packaging revenue, certain customer agreements may have intellectual property sales-based royalties and/or profit sharing consideration, collectively referred to as royalties, computed on the net product sales of the commercial partner. Royalty revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. For arrangements that include sales-based royalties where the license for intellectual property is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue when the related sales occur by the commercial partner. For arrangements that include sales-based royalties where the license for intellectual property is not deemed to be the predominant item to which the royalties relate, the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgement is required to calculate this estimated variable consideration using the most-likely amount method based on historical customer pricing and deductions and is partially constrained due to items that are outside of the Company’s control including the uncertainty of the timing of future commercial partner sales, mix of volume, customer stocking and ordering patterns, as well as unforeseen price adjustments made by the Company’s commercial partners. Revenues related to research and development are generally recognized over-time as the related services or activities are performed using the output method and in accordance with the contract terms. In agreements which specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations would be deferred and recognized over the period of performance. Milestone payments that are not within the control of the Company, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received. (h) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company manages its cash, cash equivalents and short-term investments based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are primarily concentrated amongst four customers and if any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company’s CDMO segment is dependent on its relationships with a small number of commercial partners, with its four largest customers having generated 99% of its revenues for three and nine months ended September 30, 2018. A portion of the Company’s revenues are dependent on U.S. based customers selling to end-users outside the United States. ( i ) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist primarily of funds paid to third parties for the provision of services for pre-commercialization and manufacturing scale-up activities, drug development, clinical trials, statistical analysis and report writing and regulatory filing fees and compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining product technology licenses are charged to research and development expense as acquired IPR&D if the technology licensed has not reached technological feasibility and has no alternative future use. (j) Stock-Based Awards The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Non-employee stock-based awards are revalued until an award vests and the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised. (k) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year. (l) Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average common shares outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. For the three and nine months ended September 30, 2018 and 2017, the outstanding common stock options, warrants and unvested restricted stock units have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted loss per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic and Diluted Loss Per Share Net loss $ (13,256 ) $ (9,055 ) $ (38,426 ) $ (25,997 ) Weighted average common shares outstanding, basic and diluted 20,721,330 19,058,956 20,122,569 19,053,636 Net loss per share of common stock, basic and diluted $ (0.64 ) $ (0.48 ) $ (1.91 ) $ (1.36 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2018 and 2017, as they would be anti-dilutive: September 30, 2018 2017 Options and restricted stock units outstanding 5,057,765 3,928,013 Warrants 838,664 784,928 Amounts in the table above reflect the common stock equivalents of the noted instruments. (m) Segment Information The Company determined its reportable segments based on its strategic business units, the commonalities among the products and services within each segment and the manner in which the Company reviews and evaluates operating performance. The Company has identified its CDMO and Acute Care divisions as reportable segments. Segment disclosures are included in Note 17. Segment operating profit (loss) is defined as segment revenue less segment operating expenses (segment operating expenses consist of cost of sales, general and administrative expenses, research and development expenses, and the change in valuation of contingent consideration and warrants). The following items are excluded from segment operating profit (loss): interest income and expense, and income tax benefit. Segment assets are those assets and liabilities that are recorded and reported by segment operations. Segment operating capital employed represents segment assets less segment liabilities. (n) Recent Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718) Compensation—Stock Compensation Equity-Based Payments to Non-Employees Revenue from Contracts with Customers (Topic 606) In May 2017, the FASB issued ASU No. 2017-09, “ Stock Compensation – Scope of Modification Accounting” In January 2017, the FASB issued ASU No. 2017-04 “ Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842) The Company currently expects that most of its operating lease commitments will be subject to the update and recognized as operating lease liabilities and right-of-use assets upon adoption. In May 2014, the FASB issued ASU 2014-09. ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In January 2018, the Company adopted the standard using the modified retrospective method. See Footnote 18 for additional information on the impact of the transition on the Company’s financial statements.

Acquisition of Gainesville Faci

Acquisition of Gainesville Facility and Meloxicam	9 Months Ended
	Sep. 30, 2018
Gainesville [Member]
Acquisition of Gainesville Facility and Meloxicam	(4) Acquisition of Gainesville Facility and Meloxicam On April 10, 2015, the Company completed the Gainesville Transaction. The consideration paid in connection with the Gainesville Transaction consisted of $50,000 cash at closing, a $4,000 working capital adjustment and a seven-year warrant to purchase 350,000 shares of the Company’s common stock at an exercise price of $19.46 per share. In addition, the Company may be required to pay up to an additional $125,000 in milestone payments including $45,000 upon regulatory approval of injectable meloxicam, as well as net sales milestones related to injectable meloxicam and a percentage of future product net sales related to injectable meloxicam between 10% and 12% (subject to a 30% reduction when no longer covered by patent). Under the acquisition method of accounting, the consideration paid and the fair value of the contingent consideration and royalties were allocated to the fair value of the assets acquired and liabilities assumed. The contingent consideration obligation is remeasured each reporting date with changes in fair value recognized as a period charge within the statement of operations (see Note 6 for further information regarding fair value). The contingent consideration consists of three separate components. The first component will be payable upon regulatory approval. The second component consists of three potential payments, based on the achievement of specified annual revenue targets, the last of which represents over 60% of these milestone payments and currently does not have a fair value assigned to its achievement. The third component consists of a royalty payment between 10% and 12% (subject to a 30% reduction when no longer covered by patent) for a defined term on future injectable meloxicam net sales. The fair value of the first contingent consideration component is estimated by applying a risk-adjusted discount rate to the probability-adjusted contingent payments and the expected approval dates. The fair value of the second contingent consideration component is estimated using the Monte Carlo simulation method and applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections based upon the intellectual property protection and expected revenue target attainment dates. The fair value of the third contingent consideration component recognized was estimated by applying a risk-adjusted discount rate to the potential payments resulting from revenue projections, expected intellectual property protection and the defined royalty percentage. These fair values are based on significant inputs not observable in the market, which are referred to in the guidance as Level 3 inputs. The contingent consideration components are classified as liabilities and are subject to the recognition of subsequent changes in fair value through the results of operations.

NMB Related License Agreement

NMB Related License Agreement	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
NMB Related License Agreement	(5) NMB Related License Agreement In June 2017, the Company acquired the exclusive global rights to two novel neuromuscular blocking agents, or NMBs, and a proprietary reversal agent from Cornell University, or Cornell. The NMBs and reversal agent are referred to herein as the NMB Related Compounds. The NMB Related Compounds include one novel intermediate-acting NMB that has initiated Phase I clinical trials and two other agents, a novel short-acting NMB, and a rapid-acting reversal agent specific to these NMBs. The transaction was accounted for as an asset acquisition, with the total cost of the acquisition of $766 allocated to acquired IPR&D. The Company recorded an upfront payment obligation of $350, as well as operational liabilities and acquisition-related costs of $416, primarily consisting of reimbursement to Cornell for specified past patent, legal and pre-clinical costs. In addition, the Company is obligated to make: (i) an annual license maintenance fee payment until the first commercial sale of the NMB Related Compounds; and (ii) milestone payments upon the achievement of certain milestones, up to a maximum, for each NMB, of $5,000 for U.S. regulatory approval and commercialization milestones and $3,000 for European regulatory approval and commercialization milestones. The Company is also obligated to pay Cornell royalties on net sales of the NMB Related Compounds at a rate ranging from low to mid-single digits, depending on the applicable NMB Related Compounds and whether there is a valid patent claim in the applicable country, subject to an annual minimum royalty amount. Further, the Company will reimburse Cornell ongoing patent costs related to prosecution and maintenance of the patents related to the Cornell patents for the NMB Related Compounds. The Company accounted for the transaction as an asset acquisition based on an evaluation of the accounting guidance (ASC Topic 805) and considered the early clinical stage of the novel and unproven NMB Related Compounds. The Company concluded that the acquired IPR&D of Cornell did not constitute a business as defined under ASC 805 due to the incomplete nature of the inputs and the absence of processes from a market participant perspective. Substantial additional research and development will be required to develop any NMB Related Compounds into a commercially viable drug candidate, including completion of pre-clinical testing and clinical trials, and, if such clinical trials are successful, application for regulatory approvals and manufacturing repeatability and scale-up. There is risk that a marketable compound may not be well tolerated and may never be approved. Acquired IPR&D in the asset acquisition was accounted for in accordance with FASB ASC Topic 730, “Research and Development.” At the date of acquisition, the Company determined that the development of the projects underway at Cornell had not yet reached technological feasibility and that the research in process had no alternative future uses. Accordingly, the acquired IPR&D was charged to expense in the Consolidated Statements of Operations and Comprehensive Loss on the acquisition date. The acquired IPR&D charge is expected to be deductible over a 15-year period for income tax purposes.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(6) Fair Value of Financial Instruments The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) At December 31, 2017: Assets: Cash equivalents Money market mutual funds (See Note 7) $ 38,959 $ — $ — Total cash equivalents $ 38,959 $ — $ — Short-term investments U.S. Treasury obligations (See Note 7) $ 3,498 $ — $ — Total financial assets $ 42,457 $ — $ — Liabilities: Warrants (See Note 14(d)) $ — $ — $ 3,406 Contingent consideration (See Note 4) — — 82,413 $ — $ — $ 85,819 At September 30, 2018: Assets: Cash equivalents Money market mutual funds (See Note 7) $ 25,701 $ — $ — U.S. Treasury obligations (See Note 7) 1,498 — — Commercial Paper (See Note 7) — 1,245 — Total cash equivalents $ 27,199 $ 1,245 $ — Short-term investments Commercial Paper (See Note 7) $ — $ 1,243 $ — Total financial assets $ 27,199 $ 2,488 $ — Liabilities: Warrants (See Note 14(d)) $ — $ — $ 739 Contingent consideration (See Note 4) — — 89,443 $ — $ — $ 90,182 The Company developed its own assumptions to determine the value of the warrants that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the contractual term of the warrants, risk free interest rates and dividend yield. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The reconciliation of the contingent consideration and warrants measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Consideration Balance at December 31, 2017 $ 3,406 $ 82,413 Additions — — Exercise of warrants (2,589 ) — Remeasurement (78 ) 7,030 Total at September 30, 2018 $ 739 $ 89,443 Current portion as of September 30, 2018 — 33,957 Long-term portion as of September 30, 2018 739 55,486 The current portion of the contingent consideration approximates the probability adjusted fair value amount that the Company currently expects to become payable within one year as of September 30, 2018 (see Note 4 for additional information). The Company plans to reevaluate this classification as it progresses discussions with the FDA regarding the September 2018 resubmission of its NDA and approaches the new PDUFA date of March 24, 2019. The Company follows the disclosure provisions of FASB ASC Topic 825, “ Financial Instruments

Short-term Investments

Short-term Investments	9 Months Ended
	Sep. 30, 2018
Investments Debt And Equity Securities [Abstract]
Short-term Investments	(7) Short-term Investments Short-term investments as of September 30, 2018 consist of government money market funds, U.S. Treasury obligations and commercial paper. A portion of short-term investments is included in Cash and cash equivalents due to their original maturity of three months or less when acquired. In accordance with FASB ASC Topic 320, “ Investments – Debt and Equity Securities December 31, 2017 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 38,959 $ — $ — $ 38,959 U.S. Treasury obligations 3,499 — (1 ) 3,498 Total investments $ 42,458 $ — $ (1 ) $ 42,457 September 30, 2018 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 25,701 $ — $ — $ 25,701 U.S. Treasury obligations 1,498 — — 1,498 Commercial Paper 2,488 — — 2,488 Total investments $ 29,687 $ — $ — $ 29,687 As of September 30, 2018, the Company’s investments had maturities ranging from one to three months. As of December 31, 2017, all of the Company’s investments in U.S. Treasury obligations had original maturities of less than two months. The fair value of the Company’s U.S. Treasury obligations is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, and other observable inputs. To derive the fair value of its commercial paper, the Company uses benchmark inputs and industry standard analytical models. As of September 30, 2018, there were no investments with unrealized losses.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventory	(8) Inventory Inventory is stated at the lower of cost and net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Cost is determined using the first-in, first-out method. The Company expenses costs related to inventory within the Research and development line in the Consolidated Statements of Operations and Comprehensive Loss until it receives approval from the FDA to market a product, at which time the Company commences capitalization of costs relating to that product. Inventory was as follows as of September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Raw materials $ 2,373 $ 2,130 Work in process 4,070 3,931 Finished goods 4,399 4,488 10,842 10,549 Provision for inventory obsolescence (660 ) (710 ) $ 10,182 $ 9,839 Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Inventory is ordered to meet specific customer orders and largely reflects demand. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	(9) Property, Plant and Equipment Property, plant and equipment consists of the following: September 30, 2018 December 31, 2017 Land $ 3,263 $ 3,263 Building and improvements 15,869 15,751 Furniture, office and computer equipment 6,531 5,168 Manufacturing equipment 28,900 23,391 Construction in progress 4,579 5,326 59,142 52,899 Less: accumulated depreciation and amortization 17,614 13,825 Property, plant and equipment, net $ 41,528 $ 39,074 Depreciation expense for the three and nine months ended September 30, 2018 was $1,321 and $3,819, respectively. Depreciation expense for the three and nine months ended September 30, 2017 was $1,231 and $3,655, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	(10) Intangible Assets The following represents the balance of the intangible assets at September 30, 2018: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships $ 15,500 $ 8,988 $ 6,512 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 8,988 $ 32,912 The following represents the balance of intangible assets at December 31, 2017: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships $ 15,500 $ 7,050 $ 8,450 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 7,050 $ 34,850 Amortization expense for each of the three months ended September 30, 2018 and 2017 was $646, respectively. Amortization expense for the nine months ended September 30, 2018 and 2017 was $1,938 and 1,937, respectively. As of September 30, 2018, future amortization expense is as follows: Amortization 2018 $ 646 2019 2,583 2020 2,583 2021 700 Total $ 6,512

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	(11) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: September 30, December 31, 2018 2017 Clinical trial and related costs $ 761 $ 383 Professional and consulting fees 623 1,010 Payroll and related costs 5,394 6,387 Property, plant and equipment 2,192 216 Deferred revenue 302 546 Interest payable — 802 Pre-commercialization scale-up costs 1,315 — Other research and development costs 903 — Other 805 553 $ 12,295 $ 9,897

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Long-Term Debt	(12) Long-Term Debt On November 17, 2017, the Company entered into a $100,000 Credit Agreement, or the Credit Agreement, with Athyrium Opportunities III Acquisition LP, or Athyrium. The Credit Agreement provides for an initial term loan in the original principal amount of $60,000 funded at closing. Pursuant to the terms of the Credit Agreement, there are two additional tranches of term loans, each in an aggregate original principal amount of $20,000. Based on the new PDUFA date of March 24, 2019 for the amended NDA for IV meloxicam, the Company does not currently believe it will satisfy the conditions necessary to access the additional tranches. The second tranche term loan may be drawn upon on or before December 31, 2018 provided that the Company receives regulatory approval of the Company’s IV meloxicam product candidate and will have at least $20,000 in unrestricted cash after payment of the milestone payment due to Alkermes. The third tranche term loan may be drawn upon at any time on or prior to March 31, 2020 provided that the second term loan has been drawn upon and net sales of IV meloxicam achieve $20,000 for the most recent trailing twelve-month period. The maturity date of the Credit Agreement is November 17, 2022, the five-year anniversary of the closing. The Term Loans will bear interest at a rate equal to the three-month LIBOR rate, with a 1% floor plus 9.75% per annum, with quarterly, interest-only payments until the maturity date. The unpaid principal amount of the Term Loans is due and payable on the maturity date. In addition, in accordance with the Credit Agreement the Company will have to pay a 1% exit fee of $600, which will be accreted to the carrying amount of the debt using the effective interest method over the term of the loan. In addition, if there is an early repayment, there is a sliding scale of prepayment penalties beginning with a 10% penalty and including a make-whole interest payment through the anniversary of the first two years. The Credit Agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants that the Company will need to satisfy on a monthly and quarterly basis. As of September 30, 2018, the Company was in compliance with the covenants. As of September 30, 2018, the remaining payments due under the Credit Agreement include a principal payment of $60,000 and an exit fee of $600 due at the maturity date. In connection with the Credit Agreement, the Company issued warrants to each of Athyrium and its affiliate, Athyrium Opportunities II Acquisition LP, or Athyrium II, to purchase an aggregate of 348,664 shares of the Company’s common stock with an exercise price of $8.6043 per share. See Note 14(d) for additional information. The warrants are exercisable through November 17, 2024. The initial fair value of the warrant of $2,143 was recorded as a debt issuance cost. In addition, the Company recorded debt issuance costs for the Credit Agreement of $4,439, which, along with the fair value of warrants, are being amortized using the effective interest method over the term of the Credit Agreement. Debt issuance cost amortization is included in interest expense within the Consolidated Statements of Operations and Comprehensive Loss. As of September 30, 2018, the effective interest rate was 15.82%, which takes into consideration the non-cash accretion of the exit fee and the amortization of the debt issuance cost. The components of the carrying value of the debt as of September 30, 2018, are detailed below: Principal balance outstanding $ 60,000 Unamortized deferred issuance costs (5,430 ) Exit fee accretion 105 Total $ 54,675 The Company used proceeds from the $60,000 initial term loan to (i) repay in full all outstanding indebtedness under its previous credit facility governed by the Credit Agreement, dated April 10, 2015, between the Company’s subsidiary, Recro Gainesville LLC and OrbiMed Royalty Opportunities II, LP, or the OrbiMed Credit Agreement of $31,767, which included the remaining debt principal balance of $27,347 and early termination charges of $4,420 and (ii) pay transaction fees associated with the Athyrium Credit Agreement of $4,178. Associated with the refinancing of the OrbiMed Credit Agreement and in accordance with ASC 405-20 “ Extinguishments of Liabilities The Company recorded debt issuance cost amortization for both credit agreements of $329 and $176 for the three months ended September 30, 2018 and 2017, respectively, and $987 and $502 for the nine months ended September 30, 2018 and 2017, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) Commitments and Contingencies (a) Licenses The Company is party to an exclusive license with Orion for the development and commercialization of Dexmedetomidine for use in the treatment of pain in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, but specifically excluding delivery vehicles for administration by injection or infusion, worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory. The Company is required to pay Orion lump sum payments of up to €20,500 ($23,784 as of September 30, 2018) on the achievement of certain developmental and commercial milestones, as well as a royalty on net sales during the term, which varies from 10% to 20% depending on annual sales levels. Through September 30, 2018, no such milestones have been achieved. The Company is also party to an exclusive license agreement with Orion for the development and commercialization of Fadolmidine for use as a human therapeutic, in any dosage form in the Territory. The Company is required to pay Orion lump sum payments of up to €12,200 ($14,154 as of September 30, 2018) on achievement of certain developmental and commercial milestones, as well as a royalty on net sales during the term, which varies from 10% to 15% depending on annual sales levels. Through September 30, 2018, no such milestones have been achieved. The Company is party to a license agreement with Cornell University for the exclusive license of the NMB Related Compounds. Under the terms of the agreement, the Company paid Cornell an initial upfront fee and Cornell is also entitled to receive additional milestone payments, annual license maintenance fees and royalties. See Note 5 for further information regarding these payment obligations. (b) Contingent Consideration for the Gainesville Transaction Pursuant to the purchase and sale agreement governing the Gainesville Transaction, the Company agreed to pay to Alkermes up to an additional $125,000 in milestone payments including $45,000 upon regulatory approval of injectable meloxicam, as well as net sales milestones related to injectable meloxicam and royalties on future product sales of injectable meloxicam between 10% and 12% (subject to a 30% reduction when no longer covered by patent). The Company is party to a Development, Manufacturing and Supply Agreement, or Supply Agreement, with Alkermes (through a subsidiary of Alkermes), pursuant to which Alkermes will (i) provide clinical and commercial bulk supplies of injectable meloxicam formulation and (ii) provide development services with respect to the Chemistry, Manufacturing and Controls section of an NDA for injectable meloxicam. Pursuant to the Supply Agreement, Alkermes will supply the Company with such quantities of bulk injectable meloxicam formulation as shall be reasonably required for the completion of clinical trials of injectable meloxicam. During the term of the Supply Agreement, the Company will purchase its clinical and commercial supplies of bulk injectable meloxicam formulation exclusively from Alkermes, subject to certain exceptions, for a period of time. (c) Litigation The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations. On May 31, 2018, a securities class action lawsuit was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:18-cv-02279-MMB) that purported to state a claim for alleged violations of Section 10(b) and 20(a) of the Exchange Act and Rule 10(b)(5) promulgated thereunder, based on statements made by the Company concerning the NDA for IV meloxicam. The complaint seeks unspecified damages, interest, attorneys’ fees and other costs. The Company believes that the lawsuit is without merit and intends to vigorously defend against it. The lawsuit is in the early stages and, at this time, no assessment can be made as to its likely outcome or whether the outcome will be material to the Company. (d) Leases The Company is a party to various operating leases in Malvern, Pennsylvania, Gainesville, Georgia and Dublin, Ireland for office, manufacturing, and chemistry, manufacturing and controls development space. The Company is also a party to operating leases for office equipment and storage. Rent expense includes rent as well as additional operating and tenant improvement expenses. As of September 30, 2018, future minimum lease payments excluding operating expenses and tenant improvements for the leases, are as follows: Lease payments 2018 $ 201 2019 723 2020 571 2021 523 2022 529 2023 and thereafter 404 Total $ 2,951 (e) Purchase Commitments As of September 30, 2018, the Company had outstanding non-cancelable and cancelable purchase commitments in the aggregate amount of $24,364 related to inventory, capital expenditures and other goods and services, including pre-commercial/manufacturing scale-up and clinical activities. (f) Certain Compensation and Employment Agreements The Company has entered into employment agreements with certain of its named executive officers. As of September 30, 2018, these employment agreements provided for, among other things, annual base salaries in an aggregate amount of not less than $796, from that date through calendar year 2019.

Capital Structure

Capital Structure	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Capital Structure	(14) Capital Structure (a) Common Stock The Company is authorized to issue up to 50,000,000 shares of common stock, with a par value of $0.01 per share. Reflected below are the Company’s capital raises since its initial public offering, or IPO: On March 12, 2014, the Company completed an initial public offering, or IPO, in which the Company sold 4,312,500 shares of common stock at $8.00 per share, resulting in gross proceeds of $34,500. In connection with the IPO, the Company paid $4,244 in underwriting discounts, commissions and offering expenses, resulting in net proceeds of $30,256. Also, in connection with the IPO, all of the outstanding shares of the Company’s Series A Redeemable Convertible Preferred Stock, including accreted dividends, and Bridge Notes, including accrued interest, were converted into common stock. On July 7, 2015, the Company closed a private placement with certain accredited investors in which the Company sold 1,379,311 shares of common stock at a price of $11.60 per share, for net proceeds of $14,812. The Company paid the placement agents a fee equal to 6.0% of the aggregate gross proceeds from the private placement, plus reimbursement of certain expenses. On August 19, 2016, the Company closed an underwritten public offering in which the company sold 1,986,666 shares of common stock at a price per share of $7.50, for net proceeds of $13,367 after deducting underwriting discounts, commissions and offering expenses. On December 16, 2016, the Company closed an underwritten public offering in which the company sold 6,670,000 shares of common stock at a price per share of $6.00, for net proceeds of $36,888 after deducting underwriting discounts, commissions and offering expenses. On December 29, 2017, the Company entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may sell from time to time, at its option, shares of its common stock, $0.01 par value per share, having an aggregate offering price of up to $40,000 through Cowen, as the placement agent. As of September 30, 2018, the Company did not have any sales of common stock under the Sales Agreement. (b) Common Stock Purchase Agreement On February 2, 2015, the Company entered into a Common Stock Purchase Agreement, or the 2015 Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire Capital, pursuant to which Aspire Capital was committed to purchase, at the Company’s election, up to an aggregate of $10,000 of shares of the Company’s common stock over the 24-month term of the 2015 Purchase Agreement. On the execution of the 2015 Purchase Agreement, the Company issued 96,463 shares of common stock to Aspire Capital with a fair value of $285, as consideration for entering in the 2015 Purchase Agreement. In addition, the Company incurred $253 of costs in connection with the 2015 Purchase Agreement, which, along with the fair value of the common stock, has been recorded as deferred equity costs. During 2016, the Company sold 1,143,940 shares of common stock under the 2015 Purchase Agreement for $7,796. The agreement expired in February 2017. On March 2, 2018, the Company entered into a Common Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set forth in the Purchase Agreement, Aspire Capital is committed to purchase, at the Company’s sole election, up to an aggregate of $20,000 of shares of the Company’s common stock over the approximately 30-month term of the Purchase Agreement. On the execution of the Purchase Agreement, the Company agreed to issue 33,040 shares of common stock to Aspire Capital as consideration for entering into the Purchase Agreement. As of September 30, 2018, the Company sold 1,100,000 shares of common stock under the Purchase Agreement for proceeds of $11,365, of which 50,000 shares were settled on October 1, 2018. (c) Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.01 per share. As of September 30, 2018, no preferred stock was issued or outstanding. (d) Warrants As of September 30, 2018, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date 140,000 $ 12.00 March 2019 350,000 $ 19.46 April 2022 348,664 $ 8.60 November 2024 The warrants to purchase 140,000 and 348,664 shares related to Aegis Capital Corporation and Athyrium, respectively, are equity classified. The warrants to purchase 350,000 shares related to Alkermes are liability classified since they contain a contingent net cash settlement feature. The fair value of the warrants will be remeasured through settlement or expiration with changes in fair value recognized as a period charge within the statement of operations. The following table summarizes the fair value and the assumptions used for the Black-Scholes option-pricing model for the liability classified warrants. September 30, 2018 December 31, 2017 Fair value $ 739 $ 3,406 Expected dividend yield — % — % Expected volatility 75 % 75 % Risk-free interest rates 2.91 % 2.09 % Remaining contractual term 3.50 years 4.25 years In April 2015, the Company issued a warrant to purchase 294,928 shares of common stock at an exercise price of $3.28 per share to OrbiMed in connection with the Company’s prior credit agreement, which was liability classified. In April 2018, the warrant was exercised on a cashless basis, with OrbiMed surrendering 80,213 shares, to cover the aggregate exercise price, resulting in the issuance of 214,715 shares of common stock based on the closing bid price of the Company’s Common Stock on April 27, 2018 of $12.06.

Comprehensive Loss

Comprehensive Loss	9 Months Ended
	Sep. 30, 2018
Comprehensive Income Net Of Tax [Abstract]
Comprehensive Loss	(15) Comprehensive Loss The Company’s comprehensive loss is shown on the Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017, and is comprised of net unrealized gains and losses on the Company’s available-for-sale securities. The total of comprehensive loss for the three months ended September 30, 2018 and 2017 was $13,256 and $8,987, respectively. The total of comprehensive loss for the nine months ended September 30, 2018 and 2017 was $38,425 and $26,005, respectively. There was no tax effect of other comprehensive loss for the nine months ended September 30, 2018. The tax effect of other comprehensive loss for the nine months ended September 30, 2017 was $3.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(16) Stock-Based Compensation The Company established the 2008 Stock Option Plan, or the 2008 Plan, which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. As of September 30, 2018, no stock appreciation rights have been issued. Subsequent to adoption, the 2008 Plan was amended to increase the authorized number of shares available for grant to 444,000 shares of common stock. In October 2013, the Company established the 2013 Equity Incentive Plan, or the 2013 Plan, which allows for the grant of stock options, stock appreciation rights and stock awards for a total of 600,000 shares of common stock. In June 2015, the Company’s shareholders approved the Amended and Restated Equity Incentive Plan, or the A&R Plan, which amended and restated the 2013 Plan and increased the aggregate amount of shares available for issuance to 2,000,000. On December 1 st st Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of September 30, 2018, 2,736,552 shares and 174 shares are available for future grants under the A&R Plan and 2008 Plan, respectively. The weighted average grant-date fair value of the options awarded to employees during the nine months ended September 30, 2018 and 2017 was $6.13 and $5.39, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following assumptions: September 30, 2018 2017 Range of expected option life 5.5 - 6 years 6 years Expected volatility 73.26% - 82.00% 84.71% Risk-free interest rate 2.32 - 2.98% 1.87 - 2.17% Expected dividend yield — — The following table summarizes stock option activity during the nine months ended September 30, 2018: Number of shares Weighted average exercise price Weighted average remaining contractual life Balance, December 31, 2017 3,594,875 $ 7.17 7.1 years Granted 840,461 9.24 Exercised (179,562 ) 5.89 Expired/forfeited/cancelled (283,237 ) 9.25 Balance, September 30, 2018 3,972,537 $ 7.52 7.0 years Vested 2,389,525 $ 7.02 6.0 years Vested and expected to vest 3,972,537 $ 7.52 7.0 years Included in the table above are 980,000 options granted outside the plan. The grants were made pursuant to the NASDAQ inducement grant exception in accordance with NASDAQ Listing Rule 5635(c)(4). During the year ending December 31, 2016, the Company adopted ASU 2016-09 “ Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting The following table summarizes restricted stock units, or RSUs, activity during the nine months ended September 30, 2018. Number of shares Balance, December 31, 2017 270,593 Granted 993,319 Vested and settled (133,268 ) Expired/forfeited/cancelled (45,416 ) Balance, September 30, 2018 1,085,228 Expected to vest 852,454 Included in the table above are 47,000 time-based RSUs granted outside the plan. The grants were made pursuant to the NASDAQ inducement grant exception in accordance with NASDAQ Listing Rule 5635(c)(4). In January 2018, the Company granted 242,396 time-based RSUs, which vest over four years. In March 2018, the Company granted 240,224 performance-based RSUs, which may vest based on attaining 2018 financial, clinical and operational goals. In June 2018, the Company granted 444,418 time-based RSUs, which vest in two installments at nine and 18 months from the grant date, to key employees as a retention incentive. Stock-based compensation expense for the nine months ended September 30, 2018 and 2017 was $5,250 and $4,265, respectively. As of September 30, 2018, there was $13,479 of unrecognized compensation expense related to unvested options and time-based RSUs that are expected to vest and will be expensed over a weighted average period of 2.0 years. As of September 30, 2018, there was $2,588 of unrecognized compensation expense related to unvested performance-based RSUs and will be expensed when the performance criteria are met. The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. As of September 30, 2018, the aggregate intrinsic value of the vested and unvested options was $2,606 and $194, respectively.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Reporting	(17) Segment Reporting The Company operates through two business divisions that are treated as separate financial segments: an Acute Care segment and a revenue-generating CDMO segment. The Acute Care segment is primarily focused on developing innovative products for hospital and related settings, and the CDMO segment leverages the Company’s formulation expertise to develop and manufacture pharmaceutical products using the Company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Acute Care has no revenue, and its costs consist primarily of expenses incurred in conducting the Company’s clinical and preclinical studies, acquiring clinical trial materials, regulatory activities, personnel costs and pre-commercialization of meloxicam. CDMO revenue streams are derived from manufacturing, royalty revenues, as well as CDMO segment’s research and development services performed for commercial partners. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 3). The Company evaluates performance of its reportable segments based on revenue and operating income (loss). The Company does not allocate interest income, interest expense or income taxes to its operating segments. The following table summarizes segment information as of and for the three and nine months ended September 30, 2018: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2018 2017 2018 2017 Revenues: CDMO $ 18,283 $ 17,114 $ 59,564 $ 52,790 Acute Care — — — — Total $ 18,283 $ 17,114 $ 59,564 $ 52,790 Operating income (loss): CDMO $ 6,944 $ 7,781 $ 20,799 $ 18,039 Acute Care (20,498 ) (18,484 ) (60,547 ) (45,475 ) Total $ (13,554 ) $ (10,703 ) $ (39,748 ) $ (27,436 ) Depreciation and amortization: CDMO $ 1,806 $ 1,854 $ 5,484 $ 5,556 Acute Care 161 23 273 36 Total $ 1,967 $ 1,877 $ 5,757 $ 5,592 Capital expenditures: CDMO $ 1,092 $ 1,036 $ 2,245 $ 3,932 Acute Care 340 365 2,118 654 Total $ 1,432 $ 1,401 $ 4,363 $ 4,586 September 30, December 31, 2018 2017 Total assets: CDMO $ 85,758 $ 78,136 Acute Care 89,891 108,090 Total $ 175,649 $ 186,226

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Revenue Recognition	(18) Revenue Recognition Effective January 1, 2018, the Company adopted ASU 2014-09 using the modified retrospective method applied to contracts existing as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under the new guidance while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance. See Note 3 for additional information on the Company’s revenue recognition policies. The Company uses the practical expedient to not account for significant financing components because the period between recognition and collection does not exceed one year in any contract. Upon adoption, the Company recorded a decrease of $2,818 to the opening balance of accumulated deficit as of January 1, 2018. This adjustment resulted from a change in revenue recognition associated with a variable portion of certain of its royalty revenue. Under the new accounting standard, estimated royalty revenue to be received in the future that is deemed predominantly related to product sales rather than the license for intellectual property, is included as a component of the product sale transaction consideration to the extent such consideration is not probable to significant reversal. Prior to adoption of the new guidance, the Company recognized this royalty revenue in the period the products were sold by the commercial partner. The cumulative effect of the changes made to the Company’s consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09 were as follows: Balance at December 31, 2017 Adoption of ASU 2014-09 Balance at January 1, 2018 Contract asset $ — $ 3,755 $ 3,755 Deferred income taxes 18,573 (937 ) 17,636 Total shareholders' equity 28,848 2,818 31,666 The impact of the adoption of ASU 2014-09 on the Company’s condensed consolidated statement of operations and condensed consolidated balance sheet was as follows: Previous Revenue Standard Adoption of ASU 2014-09 As Reported Three Months Ended September 30, 2018 Revenue $ 17,684 $ 599 $ 18,283 Income tax benefit 2,532 (162 ) 2,370 Net loss (13,693 ) 437 (13,256 ) Nine Months Ended September 30, 2018 Revenue $ 55,854 $ 3,710 $ 59,564 Income tax benefit 8,432 (1,002 ) 7,430 Net loss (41,134 ) 2,708 (38,426 ) September 30, 2018 Previous Revenue Standard Adoption of ASU 2014-09 As Reported Contract assets $ — $ 7,465 $ 7,465 Deferred income taxes 27,005 (1,939 ) 25,066 Total assets 170,123 5,526 175,649 Accumulated deficit (152,482 ) 5,526 (146,956 ) Total shareholders' equity 8,021 5,526 13,547 Total liabilities and shareholders' equity 170,123 5,526 175,649 Contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. Contract assets were $7,465 and $3,755 at September 30, 2018 and January 1, 2018, respectively. Generally, the contract assets balance is impacted by the recognition of additional contract assets, offset by amounts invoiced to customers or actual net product sale amounts reported by the commercial partner for the period. For the nine months ended September 30, 2018, actual net product sale amounts reported by the Company’s commercial partner exceeded estimates of royalty amounts attributed to manufactured product shipped as of January 1, 2018 for the related arrangements by approximately $817. The following table presents changes in the Company’s contract assets for the nine months ended September 30, 2018: Contract asset, beginning of year $ 3,755 Change in estimate arising from changes in transaction price 817 Reclassification of contract asset to receivables, as the result of rights to consideration becoming unconditional (4,572 ) Contract assets recognized 7,465 Contract asset, end of period $ 7,465 The following table disaggregates revenue by business segment and timing of revenue recognition: Three Months Ended September 30, 2018 Point in time Over time Total CDMO $ 18,086 $ 197 $ 18,283 Acute Care — — — Revenue 18,086 197 18,283 Nine Months Ended September 30, 2018 Point in time Over time Total CDMO $ 58,876 $ 688 $ 59,564 Acute Care — — — Revenue 58,876 688 59,564 Adoption of ASU 2014-09 did not require capitalization of any costs to obtain or fulfill contracts. In general, the Company’s payment terms for manufacturing revenue and research and development services is 30 days. Royalty revenue is recorded to accounts receivable in the quarter that the product is sold by the commercial partner upon reporting from the commercial partner and payment terms are generally 45 days after quarter end. Based on the adoption of ASU 2014-09, the timing difference between recognition of certain royalty revenues as a contract asset and cash receipt is increased by an estimated 90 days.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	(19) Related Party Transactions A Non-Executive Director of the Company’s Irish subsidiary is a Managing Director and a majority shareholder of HiTech Health Ltd, or HiTech Health, a consultancy firm for the biotech, pharmaceutical and medical device industry. Since 2016, HiTech Health has provided the Company with certain consulting services and in November 2017 both parties entered into a Service Agreement to engage in both regulatory and supply chain project support and consultancy. In consideration for such services, the Company recorded $25 and $278 for the three and nine months ended September 30, 2018, respectively. A portion of the amount relates to consultancy services provided by the Non-Executive Director.

Retirement Plan

Retirement Plan	9 Months Ended
	Sep. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Retirement Plan	(20) Retirement Plan The Company has a voluntary 401(k) Savings Plan (the 401(k) Plan) in which all employees are eligible to participate. The Company’s policy is to match 100% of the employee contributions up to a maximum of 5% of employee compensation. Total Company contributions to the 401(k) plan for the three months ended September 30, 2018 and 2017 were $258 and $208, respectively. The Company contributions for the nine months ended September 30, 2018 and 2017 were $959 and $759, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of Form 10-Q and Article 10 of Regulation S-X and, therefore, do not include all of the information and notes required by U.S. GAAP for complete annual financial statements. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2018. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
Use of Estimates	(b) Use of Estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.
Cash and Cash Equivalents	(c) Cash and Cash Equivalents Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value because of the changes in interest rates.
Property and Equipment	(d) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture and office equipment; six to ten or more years for manufacturing equipment; two to five years for vehicles; 35 to 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred.
Business Combinations	(e) Business Combinations In accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805, “Business Combinations,” or ASC 805, the Company allocates the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make significant estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from management of the acquired companies and expectations of future cash flows. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. In-process research and development, or IPR&D, is the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D requires the Company to make significant estimates. In a business combination, the Company capitalizes IPR&D as an intangible asset, and for an asset acquisition the Company expenses IPR&D in the Consolidated Statements of Operations and Comprehensive Loss on the acquisition date.
Goodwill and Intangible Assets	(f) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a two-step method for determining impairment. The first step compares a reporting unit’s fair value to its carrying amount to identify potential goodwill impairment. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the second step of the impairment test must be completed to measure the amount of the reporting unit’s goodwill impairment loss, if any. Step two requires an assignment of the reporting unit’s fair value to the reporting unit’s assets and liabilities to determine the implied fair value of the reporting unit’s goodwill. The implied fair value of the reporting unit’s goodwill is then compared with the carrying amount of the reporting unit’s goodwill to determine the goodwill impairment loss to be recognized, if any. Intangible assets include the Company’s royalties and contract manufacturing relationships intangible asset as well as an IPR&D asset. The royalties and contract manufacturing relationships intangible asset is considered a definite-lived intangible asset and is amortized on a straight-line basis over a useful life of six years. Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its Consolidated Statements of Operations and Comprehensive Loss. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test, which compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. Based on accounting standards, it is required that these assets be assessed at least annually for impairment unless a triggering event occurs between annual assessments, which would then require an assessment in the period which a triggering event occurred. The Company performs its annual goodwill and indefinite-lived intangible asset impairment test as of November 30 th
Revenue Recognition	(g) Revenue Recognition The Company generates revenues from manufacturing, packaging, research and development, and related services for multiple pharmaceutical companies through its CDMO segment. The agreements that the Company has with its commercial partners provide for manufacturing revenues, sales-based royalties and/or profit sharing components. The Company’s revenue policies listed below are reflective of Accounting Standards Update, or ASU, No. 2014-09, “ Revenue from Contracts with Customers,” Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include pricing and volume-based adjustments. In addition to manufacturing and packaging revenue, certain customer agreements may have intellectual property sales-based royalties and/or profit sharing consideration, collectively referred to as royalties, computed on the net product sales of the commercial partner. Royalty revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. For arrangements that include sales-based royalties where the license for intellectual property is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue when the related sales occur by the commercial partner. For arrangements that include sales-based royalties where the license for intellectual property is not deemed to be the predominant item to which the royalties relate, the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgement is required to calculate this estimated variable consideration using the most-likely amount method based on historical customer pricing and deductions and is partially constrained due to items that are outside of the Company’s control including the uncertainty of the timing of future commercial partner sales, mix of volume, customer stocking and ordering patterns, as well as unforeseen price adjustments made by the Company’s commercial partners. Revenues related to research and development are generally recognized over-time as the related services or activities are performed using the output method and in accordance with the contract terms. In agreements which specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations would be deferred and recognized over the period of performance. Milestone payments that are not within the control of the Company, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received.
Concentration of Credit Risk	(h) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company manages its cash, cash equivalents and short-term investments based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are primarily concentrated amongst four customers and if any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company’s CDMO segment is dependent on its relationships with a small number of commercial partners, with its four largest customers having generated 99% of its revenues for three and nine months ended September 30, 2018. A portion of the Company’s revenues are dependent on U.S. based customers selling to end-users outside the United States.
Research and Development	( i ) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist primarily of funds paid to third parties for the provision of services for pre-commercialization and manufacturing scale-up activities, drug development, clinical trials, statistical analysis and report writing and regulatory filing fees and compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining product technology licenses are charged to research and development expense as acquired IPR&D if the technology licensed has not reached technological feasibility and has no alternative future use.
Stock-Based Awards	(j) Stock-Based Awards The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Non-employee stock-based awards are revalued until an award vests and the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised.
Income Taxes	(k) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.
Net Income Per Common Share	(l) Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average common shares outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. For the three and nine months ended September 30, 2018 and 2017, the outstanding common stock options, warrants and unvested restricted stock units have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted loss per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic and Diluted Loss Per Share Net loss $ (13,256 ) $ (9,055 ) $ (38,426 ) $ (25,997 ) Weighted average common shares outstanding, basic and diluted 20,721,330 19,058,956 20,122,569 19,053,636 Net loss per share of common stock, basic and diluted $ (0.64 ) $ (0.48 ) $ (1.91 ) $ (1.36 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2018 and 2017, as they would be anti-dilutive: September 30, 2018 2017 Options and restricted stock units outstanding 5,057,765 3,928,013 Warrants 838,664 784,928 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Segment Information	(m) Segment Information The Company determined its reportable segments based on its strategic business units, the commonalities among the products and services within each segment and the manner in which the Company reviews and evaluates operating performance. The Company has identified its CDMO and Acute Care divisions as reportable segments. Segment disclosures are included in Note 17. Segment operating profit (loss) is defined as segment revenue less segment operating expenses (segment operating expenses consist of cost of sales, general and administrative expenses, research and development expenses, and the change in valuation of contingent consideration and warrants). The following items are excluded from segment operating profit (loss): interest income and expense, and income tax benefit. Segment assets are those assets and liabilities that are recorded and reported by segment operations. Segment operating capital employed represents segment assets less segment liabilities.
Recent Accounting Pronouncements	(n) Recent Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718) Compensation—Stock Compensation Equity-Based Payments to Non-Employees Revenue from Contracts with Customers (Topic 606) In May 2017, the FASB issued ASU No. 2017-09, “ Stock Compensation – Scope of Modification Accounting” In January 2017, the FASB issued ASU No. 2017-04 “ Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842) The Company currently expects that most of its operating lease commitments will be subject to the update and recognized as operating lease liabilities and right-of-use assets upon adoption. In May 2014, the FASB issued ASU 2014-09. ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In January 2018, the Company adopted the standard using the modified retrospective method. See Footnote 18 for additional information on the impact of the transition on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Computation of Basic and Diluted Loss Per Share	The following table sets forth the computation of basic and diluted loss per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic and Diluted Loss Per Share Net loss $ (13,256 ) $ (9,055 ) $ (38,426 ) $ (25,997 ) Weighted average common shares outstanding, basic and diluted 20,721,330 19,058,956 20,122,569 19,053,636 Net loss per share of common stock, basic and diluted $ (0.64 ) $ (0.48 ) $ (1.91 ) $ (1.36 )
Schedule of Anti-Dilutive Securities	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2018 and 2017, as they would be anti-dilutive: September 30, 2018 2017 Options and restricted stock units outstanding 5,057,765 3,928,013 Warrants 838,664 784,928

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis	The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) At December 31, 2017: Assets: Cash equivalents Money market mutual funds (See Note 7) $ 38,959 $ — $ — Total cash equivalents $ 38,959 $ — $ — Short-term investments U.S. Treasury obligations (See Note 7) $ 3,498 $ — $ — Total financial assets $ 42,457 $ — $ — Liabilities: Warrants (See Note 14(d)) $ — $ — $ 3,406 Contingent consideration (See Note 4) — — 82,413 $ — $ — $ 85,819 At September 30, 2018: Assets: Cash equivalents Money market mutual funds (See Note 7) $ 25,701 $ — $ — U.S. Treasury obligations (See Note 7) 1,498 — — Commercial Paper (See Note 7) — 1,245 — Total cash equivalents $ 27,199 $ 1,245 $ — Short-term investments Commercial Paper (See Note 7) $ — $ 1,243 $ — Total financial assets $ 27,199 $ 2,488 $ — Liabilities: Warrants (See Note 14(d)) $ — $ — $ 739 Contingent consideration (See Note 4) — — 89,443 $ — $ — $ 90,182
Reconciliation of Contingent Consideration and Warrants Measured at Fair Value on Recurring Basis Using Unobservable Inputs	The reconciliation of the contingent consideration and warrants measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Consideration Balance at December 31, 2017 $ 3,406 $ 82,413 Additions — — Exercise of warrants (2,589 ) — Remeasurement (78 ) 7,030 Total at September 30, 2018 $ 739 $ 89,443 Current portion as of September 30, 2018 — 33,957 Long-term portion as of September 30, 2018 739 55,486

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Sep. 30, 2018
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The following is a summary of available-for-sale securities: December 31, 2017 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 38,959 $ — $ — $ 38,959 U.S. Treasury obligations 3,499 — (1 ) 3,498 Total investments $ 42,458 $ — $ (1 ) $ 42,457 September 30, 2018 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 25,701 $ — $ — $ 25,701 U.S. Treasury obligations 1,498 — — 1,498 Commercial Paper 2,488 — — 2,488 Total investments $ 29,687 $ — $ — $ 29,687

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Components of Inventory	Inventory was as follows as of September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Raw materials $ 2,373 $ 2,130 Work in process 4,070 3,931 Finished goods 4,399 4,488 10,842 10,549 Provision for inventory obsolescence (660 ) (710 ) $ 10,182 $ 9,839

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: September 30, 2018 December 31, 2017 Land $ 3,263 $ 3,263 Building and improvements 15,869 15,751 Furniture, office and computer equipment 6,531 5,168 Manufacturing equipment 28,900 23,391 Construction in progress 4,579 5,326 59,142 52,899 Less: accumulated depreciation and amortization 17,614 13,825 Property, plant and equipment, net $ 41,528 $ 39,074

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Balance of Intangible Assets	The following represents the balance of the intangible assets at September 30, 2018: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships $ 15,500 $ 8,988 $ 6,512 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 8,988 $ 32,912 The following represents the balance of intangible assets at December 31, 2017: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships $ 15,500 $ 7,050 $ 8,450 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 7,050 $ 34,850
Schedule of Future Amortization Expense	As of September 30, 2018, future amortization expense is as follows: Amortization 2018 $ 646 2019 2,583 2020 2,583 2021 700 Total $ 6,512

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: September 30, December 31, 2018 2017 Clinical trial and related costs $ 761 $ 383 Professional and consulting fees 623 1,010 Payroll and related costs 5,394 6,387 Property, plant and equipment 2,192 216 Deferred revenue 302 546 Interest payable — 802 Pre-commercialization scale-up costs 1,315 — Other research and development costs 903 — Other 805 553 $ 12,295 $ 9,897

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Balance	The components of the carrying value of the debt as of September 30, 2018, are detailed below: Principal balance outstanding $ 60,000 Unamortized deferred issuance costs (5,430 ) Exit fee accretion 105 Total $ 54,675

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments, Excluding Operating Expenses and Tenant Improvements	As of September 30, 2018, future minimum lease payments excluding operating expenses and tenant improvements for the leases, are as follows: Lease payments 2018 $ 201 2019 723 2020 571 2021 523 2022 529 2023 and thereafter 404 Total $ 2,951

Capital Structure (Tables)

Capital Structure (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Schedule of Warrants Outstanding to Purchase Shares of Common Stock	As of September 30, 2018, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date 140,000 $ 12.00 March 2019 350,000 $ 19.46 April 2022 348,664 $ 8.60 November 2024
Summary of Fair Value and Assumptions Used for Black-Scholes Option-pricing Model for Liability Classified Warrants	The following table summarizes the fair value and the assumptions used for the Black-Scholes option-pricing model for the liability classified warrants. September 30, 2018 December 31, 2017 Fair value $ 739 $ 3,406 Expected dividend yield — % — % Expected volatility 75 % 75 % Risk-free interest rates 2.91 % 2.09 % Remaining contractual term 3.50 years 4.25 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model	The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following assumptions: September 30, 2018 2017 Range of expected option life 5.5 - 6 years 6 years Expected volatility 73.26% - 82.00% 84.71% Risk-free interest rate 2.32 - 2.98% 1.87 - 2.17% Expected dividend yield — —
Summary of Stock Option Activity	The following table summarizes stock option activity during the nine months ended September 30, 2018: Number of shares Weighted average exercise price Weighted average remaining contractual life Balance, December 31, 2017 3,594,875 $ 7.17 7.1 years Granted 840,461 9.24 Exercised (179,562 ) 5.89 Expired/forfeited/cancelled (283,237 ) 9.25 Balance, September 30, 2018 3,972,537 $ 7.52 7.0 years Vested 2,389,525 $ 7.02 6.0 years Vested and expected to vest 3,972,537 $ 7.52 7.0 years
Summary of Restricted Stock Units Activity	The following table summarizes restricted stock units, or RSUs, activity during the nine months ended September 30, 2018. Number of shares Balance, December 31, 2017 270,593 Granted 993,319 Vested and settled (133,268 ) Expired/forfeited/cancelled (45,416 ) Balance, September 30, 2018 1,085,228 Expected to vest 852,454

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Summary of Segment Information	The following table summarizes segment information as of and for the three and nine months ended September 30, 2018: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2018 2017 2018 2017 Revenues: CDMO $ 18,283 $ 17,114 $ 59,564 $ 52,790 Acute Care — — — — Total $ 18,283 $ 17,114 $ 59,564 $ 52,790 Operating income (loss): CDMO $ 6,944 $ 7,781 $ 20,799 $ 18,039 Acute Care (20,498 ) (18,484 ) (60,547 ) (45,475 ) Total $ (13,554 ) $ (10,703 ) $ (39,748 ) $ (27,436 ) Depreciation and amortization: CDMO $ 1,806 $ 1,854 $ 5,484 $ 5,556 Acute Care 161 23 273 36 Total $ 1,967 $ 1,877 $ 5,757 $ 5,592 Capital expenditures: CDMO $ 1,092 $ 1,036 $ 2,245 $ 3,932 Acute Care 340 365 2,118 654 Total $ 1,432 $ 1,401 $ 4,363 $ 4,586 September 30, December 31, 2018 2017 Total assets: CDMO $ 85,758 $ 78,136 Acute Care 89,891 108,090 Total $ 175,649 $ 186,226

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
Schedule of Changes in Contract Assets	The following table presents changes in the Company’s contract assets for the nine months ended September 30, 2018: Contract asset, beginning of year $ 3,755 Change in estimate arising from changes in transaction price 817 Reclassification of contract asset to receivables, as the result of rights to consideration becoming unconditional (4,572 ) Contract assets recognized 7,465 Contract asset, end of period $ 7,465
Disaggregation of Revenue by Business Segment and Timing of Revenue Recognition	The following table disaggregates revenue by business segment and timing of revenue recognition: Three Months Ended September 30, 2018 Point in time Over time Total CDMO $ 18,086 $ 197 $ 18,283 Acute Care — — — Revenue 18,086 197 18,283 Nine Months Ended September 30, 2018 Point in time Over time Total CDMO $ 58,876 $ 688 $ 59,564 Acute Care — — — Revenue 58,876 688 59,564
ASU 2014-09 [Member]
Impact of Adoption of ASU on Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet	The cumulative effect of the changes made to the Company’s consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09 were as follows: Balance at December 31, 2017 Adoption of ASU 2014-09 Balance at January 1, 2018 Contract asset $ — $ 3,755 $ 3,755 Deferred income taxes 18,573 (937 ) 17,636 Total shareholders' equity 28,848 2,818 31,666 The impact of the adoption of ASU 2014-09 on the Company’s condensed consolidated statement of operations and condensed consolidated balance sheet was as follows: Previous Revenue Standard Adoption of ASU 2014-09 As Reported Three Months Ended September 30, 2018 Revenue $ 17,684 $ 599 $ 18,283 Income tax benefit 2,532 (162 ) 2,370 Net loss (13,693 ) 437 (13,256 ) Nine Months Ended September 30, 2018 Revenue $ 55,854 $ 3,710 $ 59,564 Income tax benefit 8,432 (1,002 ) 7,430 Net loss (41,134 ) 2,708 (38,426 ) September 30, 2018 Previous Revenue Standard Adoption of ASU 2014-09 As Reported Contract assets $ — $ 7,465 $ 7,465 Deferred income taxes 27,005 (1,939 ) 25,066 Total assets 170,123 5,526 175,649 Accumulated deficit (152,482 ) 5,526 (146,956 ) Total shareholders' equity 8,021 5,526 13,547 Total liabilities and shareholders' equity 170,123 5,526 175,649

Background - Additional Informa

Background - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Entity incorporation date	Nov. 15, 2007
Number of operating divisions	2

Development-Stage Risks and L_2

Development-Stage Risks and Liquidity - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Business Developments Risks And Uncertainties Liquidity [Abstract]
Accumulated deficit	$ 146,956	$ 111,348

Summary of Significant Accoun_4

Summary of Significant Accounting Principles - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2018Customer	Sep. 30, 2018USD ($)Customer
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Goodwill impairment | $		$ 0
Indefinite-lived intangible assets impairment | $		$ 0
Accounts Receivable [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers | Customer		4
Sales Revenue, Net [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers | Customer	4	4
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage	99.00%	99.00%
Royalties and Contract Manufacturing Relationships [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Definite-lived intangible asset, useful lives		6 years
Furniture and Office Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		3 years
Furniture and Office Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		10 years
Manufacturing Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		6 years
Manufacturing Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life		ten or more years
Vehicles [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		2 years
Vehicles [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		5 years
Buildings [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		35 years
Buildings [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		40 years
Leasehold Improvements [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life		the shorter of the lease term or useful life

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Computation of Basic and Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Basic and Diluted Loss Per Share
Net loss	$ (13,256)	$ (9,055)	$ (38,426)	$ (25,997)
Weighted average common shares outstanding, basic and diluted	20,721,330	19,058,956	20,122,569	19,053,636
Net loss per share of common stock, basic and diluted	$ (0.64)	$ (0.48)	$ (1.91)	$ (1.36)

Summary of Significant Accoun_6

Summary of Significant Accounting Principles - Schedule of Anti-Dilutive Securities (Detail) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Options [Member] | Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	5,057,765	3,928,013
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	838,664	784,928

Acquisition of Gainesville Fa_2

Acquisition of Gainesville Facility and Meloxicam - Additional Information (Detail) - Gainesville [Member] $ / shares in Units, $ in Thousands	Apr. 10, 2015USD ($)$ / sharesshares
Business Acquisition [Line Items]
Business acquisition upfront payment in cash	$ 50,000
Working capital adjustment	4,000
Business acquisition contingent consideration possible milestone payments	$ 125,000
Maximum future net product sales milestone percentage	30.00%
Minimum milestone payments percentage	60.00%
Maximum royalty payment percentage	30.00%
Minimum [Member]
Business Acquisition [Line Items]
Future net product sales milestone percentage	10.00%
Royalty payment percentage	10.00%
Maximum [Member]
Business Acquisition [Line Items]
Future net product sales milestone percentage	12.00%
Royalty payment percentage	12.00%
Regulatory Approval and Net Sales Milestones [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45,000
Seven Year Warrant [Member]
Business Acquisition [Line Items]
Purchase common stock with warrant issue | shares	350,000
Warrant, exercise price per share | $ / shares	$ 19.46

NMB Related License Agreement -

NMB Related License Agreement - Additional Information (Detail) - Cornell University [Member] - Neuromuscular Blocking Agents License Agreement [Member]	1 Months Ended
	Jun. 30, 2017USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Acquired IPR&D	$ 766,000
Upfront payment obligation	350,000
Operational liabilities and acquisition-related costs	$ 416,000
Acquired IPR&D charge expected deductible period for income tax purposes	15 years
U.S [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory approval and commercialization milestones	$ 5,000,000
European [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory approval and commercialization milestones	$ 3,000,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Assets:
Total financial assets	$ 29,687	$ 42,457
Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrants	739	3,406
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Total cash equivalents	27,199	38,959
Total financial assets	27,199	42,457
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Mutual Funds [Member]
Assets:
Total cash equivalents	25,701	38,959
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Treasury Obligations [Member]
Assets:
Total cash equivalents	1,498
Short-term investments		3,498
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets:
Total cash equivalents	1,245
Total financial assets	2,488
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member]
Assets:
Total cash equivalents	1,245
Short-term investments	1,243
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Warrants	739	3,406
Contingent consideration	89,443	82,413
Liabilities	$ 90,182	$ 85,819

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Reconciliation of Contingent Consideration and Warrants Measured at Fair Value on Recurring Basis Using Unobservable Inputs (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Warrants [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Balance at December 31, 2017	$ 3,406
Exercise of warrants	(2,589)
Remeasurement	(78)
Total at September 30, 2018	739
Long-term portion as of September 30, 2018	739
Contingent Consideration [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Balance at December 31, 2017	82,413
Remeasurement	7,030
Total at September 30, 2018	89,443
Current portion as of September 30, 2018	33,957
Long-term portion as of September 30, 2018	$ 55,486

Short-term Investments - Summar

Short-term Investments - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 29,687	$ 42,458
Gross Unrealized Loss		(1)
Estimated Fair Value	29,687	42,457
Money Market Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	25,701	38,959
Estimated Fair Value	25,701	38,959
U.S. Treasury Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,498	3,499
Gross Unrealized Loss		(1)
Estimated Fair Value	1,498	$ 3,498
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,488
Estimated Fair Value	$ 2,488

Short-term Investments - Additi

Short-term Investments - Additional Information (Detail) - Investment	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Number of investments with unrealized losses position, less than 12 months	0
Minimum [Member]
Schedule of Available-for-sale Securities [Line Items]
Investments maturities period	1 month
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Investments maturities period	3 months
U.S. Treasury Obligations [Member] | Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Investments maturities period		2 months

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 2,373	$ 2,130
Work in process	4,070	3,931
Finished goods	4,399	4,488
Inventory	10,842	10,549
Provision for inventory obsolescence	(660)	(710)
Inventory, net	$ 10,182	$ 9,839

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 59,142	$ 52,899
Less: accumulated depreciation and amortization	17,614	13,825
Property, plant and equipment, net	41,528	39,074
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,263	3,263
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	15,869	15,751
Furniture, Office & Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	6,531	5,168
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	28,900	23,391
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,579	$ 5,326

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation expense	$ 1,321	$ 1,231	$ 3,819	$ 3,655

Intangible Assets - Summary of

Intangible Assets - Summary of Balance of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Cost, Total	$ 41,900	$ 41,900
Accumulated Amortization	8,988	7,050
Net Intangible Assets, Total	32,912	34,850
Royalties and Contract Manufacturing Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost, Definite-lived	15,500	15,500
Accumulated Amortization	8,988	7,050
Net Intangible Assets, Definite-lived	6,512	8,450
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Indefinite-lived	$ 26,400	$ 26,400

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Intangible Assets Net Excluding Goodwill [Abstract]
Amortization expense	$ 646	$ 646	$ 1,938	$ 1,937

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization Expense (Detail) - Royalties and Contract Manufacturing Relationships [Member] - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
2,018	$ 646
2,019	2,583
2,020	2,583
2,021	700
Total	$ 6,512	$ 8,450

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Clinical trial and related costs	$ 761	$ 383
Professional and consulting fees	623	1,010
Payroll and related costs	5,394	6,387
Property, plant and equipment	2,192	216
Deferred revenue	302	546
Interest payable		802
Pre-commercialization scale-up costs	1,315
Other research and development costs	903
Other	805	553
Total accrued expenses and other current liabilities	$ 12,295	$ 9,897

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail)	Nov. 17, 2017USD ($)Tranche	Apr. 10, 2015	Sep. 30, 2018USD ($)$ / shares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Debt instrument, exit fee			$ 105,000		$ 105,000
Principal balance outstanding			60,000,000		60,000,000
Payments of debt transaction fees					261,000
Amortization of debt issuance costs			$ 329,000	$ 176,000	$ 987,000	$ 502,000
Athyrium Opportunities II Acquisition LP | Seven Year Warrant [Member]
Debt Instrument [Line Items]
Purchase common stock with warrant issue | shares					348,664
Warrant, exercise price per share | $ / shares			$ 8.6043		$ 8.6043
Warrants, exercisable date					Nov. 17, 2024
Athyrium Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 100,000,000
Number of additional tranches | Tranche	2
Debt instrument, maturity date	Nov. 17, 2022
Debt instrument, maturity term	5 years
Term loan interest rate, Description					interest at a rate equal to the three-month LIBOR rate, with a 1% floor plus 9.75% per annum
Debt instrument, frequency of interest payment					quarterly
Exit fee percentage	1.00%
Debt instrument, exit fee	$ 600,000		$ 600,000		$ 600,000
Debt instrument, covenant description					The Credit Agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants that the Company will need to satisfy on a monthly and quarterly basis. As of September 30, 2018, the Company was in compliance with the covenants
Debt instrument early repayment of prepayment penalty percentage					10.00%
Debt instrument, make whole interest payment period					2 years
Principal balance outstanding			60,000,000		$ 60,000,000
Debt issuance costs related to credit agreement			$ 4,439,000		$ 4,439,000
Effective interest rate			15.82%		15.82%
Payments of debt transaction fees					$ 4,178,000
Athyrium Credit Agreement [Member] | Warrants [Member]
Debt Instrument [Line Items]
Initial warrant fair value			$ 2,143,000		$ 2,143,000
Athyrium Credit Agreement [Member] | Floor [Member]
Debt Instrument [Line Items]
Term loan variable interest rate					1.00%
Athyrium Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate					9.75%
Athyrium Credit Agreement [Member] | Tranche One Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	60,000,000
Athyrium Credit Agreement [Member] | Tranche Two Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	20,000,000
Athyrium Credit Agreement [Member] | Tranche Two Term Loan [Member] | Alkermes Plc [Member]
Debt Instrument [Line Items]
Debt instrument, unrestricted cash			$ 20,000,000		$ 20,000,000
Athyrium Credit Agreement [Member] | Tranche Three Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 20,000,000
Athyrium Credit Agreement [Member] | Tranche Three Term Loan [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Debt instrument, net sales							$ 20,000,000
OrbiMed Credit Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of initial term loan					60,000,000
Term loan agreement date		Apr. 10, 2015
Repayments of debt and early termination charges					31,767,000
Repayments of debt Principal balance					27,347,000
Prepayment of debt and debt extinguishment costs					$ 4,420,000
OrbiMed Credit Agreement [Member] | Interest Expense [Member]
Debt Instrument [Line Items]
Loss on early extinguishment of debt								$ 6,772,000

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt Balance (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Principal balance outstanding	$ 60,000
Unamortized deferred issuance costs	(5,430)
Exit fee accretion	105
Total	$ 54,675	$ 53,598

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2018EUR (€)
Purchase Commitment [Member]
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable	$ 24,364,000
Gainesville Transaction [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones	$ 125,000,000
Maximum future net product sales milestone percentage	30.00%	30.00%
Gainesville Transaction [Member] | Regulatory Approval and Net Sales Milestones [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones	$ 45,000,000
Minimum [Member] | Gainesville Transaction [Member]
Supply Commitment [Line Items]
Future net product sales milestone percentage	10.00%	10.00%
Maximum [Member] | Executive Officer [Member]
Supply Commitment [Line Items]
Aggregate annual base salaries of employment agreement	$ 796,000
Maximum [Member] | Gainesville Transaction [Member]
Supply Commitment [Line Items]
Future net product sales milestone percentage	12.00%	12.00%
Dexmedetomidine License Agreement [Member]
Supply Commitment [Line Items]
Contingent milestone payments, maximum	$ 23,784,000	€ 20,500,000
Amount of royalty payments due or payable	$ 0
Dexmedetomidine License Agreement [Member] | Minimum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments	10.00%	10.00%
Dexmedetomidine License Agreement [Member] | Maximum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments	20.00%	20.00%
Fadolmidine License Agreement [Member]
Supply Commitment [Line Items]
Amount of royalty payments due or payable	$ 0
Additional contingent milestones payment	$ 14,154,000	€ 12,200,000
Fadolmidine License Agreement [Member] | Minimum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments	10.00%	10.00%
Fadolmidine License Agreement [Member] | Maximum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments	15.00%	15.00%

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments, Excluding Operating Expenses and Tenant Improvements (Detail) $ in Thousands	Sep. 30, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,018	$ 201
2,019	723
2,020	571
2,021	523
2,022	529
2023 and thereafter	404
Lease payments, Total	$ 2,951

Capital Structure - Additional

Capital Structure - Additional Information (Detail) - USD ($)

Oct. 01, 2018

Mar. 02, 2018

Dec. 29, 2017

Dec. 16, 2016

Aug. 19, 2016

Jul. 07, 2015

Feb. 02, 2015

Mar. 12, 2014

Apr. 30, 2018

Sep. 30, 2018

Dec. 31, 2016

Apr. 27, 2018

Dec. 31, 2017

Apr. 30, 2015

Schedule Of Capitalization Equity [Line Items]

Common stock, shares authorized

50,000,000

50,000,000

Common stock, par value

$ 0.01

$ 0.01

Common stock issuance

$ 11,500,000

Proceeds from sale of common stock, net of transaction costs

11,331,000

Stock issued at fair value

$ 357,000

Preferred stock, shares authorized

10,000,000

10,000,000

Preferred stock, par value

$ 0.01

$ 0.01

Preferred stock, shares issued

0

0

Preferred stock, shares outstanding

0

0

Common Stock [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance, shares

1,083,040

Common stock issuance

$ 11,000

Cashless warrants exercised for shares of common stock

214,715

Warrants, Exercise Price $12.00, Expiring on March 2019 [Member]

Schedule Of Capitalization Equity [Line Items]

Warrants outstanding to purchase shares, Number of Shares

140,000

Warrant, exercise price per share

$ 12

Warrants, Exercise Price $8.60, Expiring on November 2024 [Member]

Schedule Of Capitalization Equity [Line Items]

Warrants outstanding to purchase shares, Number of Shares

348,664

Warrants, Exercise Price $19.46, Expiring on April 2022 [Member]

Schedule Of Capitalization Equity [Line Items]

Warrants outstanding to purchase shares, Number of Shares

350,000

Warrant, exercise price per share

$ 19.46

Cowen and Company, LLC [member]

Schedule Of Capitalization Equity [Line Items]

Common stock, par value

$ 0.01

Common stock issuance, shares

0

Aspire Capital [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance, shares

33,040

96,463

1,100,000

1,143,940

Common stock issuance

$ 7,796

Proceeds from sale of common stock, net of transaction costs

$ 11,365,000

Term of purchase agreement

30 months

24 months

Stock issued at fair value

$ 285,000

Cost incurred in stock issuance

253,000

Aspire Capital [Member] | Subsequent Event [Member]

Schedule Of Capitalization Equity [Line Items]

Shares, settled

50,000

OrbiMed [Member] | Common Stock [Member]

Schedule Of Capitalization Equity [Line Items]

Warrant to purchase shares of common stock

294,928

Warrant, exercise price per share

$ 3.28

Common stock warrants repurchase

80,213

Cashless warrants exercised for shares of common stock

214,715

Common stock share price

$ 12.06

Investor [Member]

Schedule Of Capitalization Equity [Line Items]

Aggregate net proceeds from private placement

$ 14,812,000

Placement agents fee percentage

6.00%

Initial Public Offering (IPO) [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance, shares

4,312,500

Sale of stock, price per share

$ 8

Gross proceeds on sale of common stock in initial public offering

$ 34,500,000

Payments on underwriting discounts, commissions and offering expenses

4,244,000

Common stock issuance

$ 30,256,000

Private Placement [Member] | Investor [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance, shares

1,379,311

Common stock issuance price

$ 11.60

Underwritten Public Offering [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance, shares

6,670,000

1,986,666

Common stock issuance price

$ 6

$ 7.50

Proceeds from sale of common stock, net of transaction costs

$ 36,888,000

$ 13,367,000

Maximum [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock, shares authorized

50,000,000

Maximum [Member] | Cowen and Company, LLC [member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance

$ 40,000,000

Maximum [Member] | Aspire Capital [Member]

Schedule Of Capitalization Equity [Line Items]

Common stock issuance

$ 20,000,000

$ 10,000,000

Capital Structure - Schedule of

Capital Structure - Schedule of Warrants Outstanding to Purchase Shares of Common Stock (Detail)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Warrants, Exercise Price $12.00, Expiring on March 2019 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	140,000
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 12
Warrants outstanding to purchase shares, Expiration Date	2019-03
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	350,000
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 19.46
Warrants outstanding to purchase shares, Expiration Date	2022-04
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	348,664
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 8.60
Warrants outstanding to purchase shares, Expiration Date	2024-11

Capital Structure - Summary of

Capital Structure - Summary of Fair Value and Assumptions Used for Black-Scholes Option-pricing Model for Liability Classified Warrants (Detail) $ in Thousands	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Warrants and Rights Outstanding, Type [Extensible List]	reph:BlackScholesOptionPricingModelMember	reph:BlackScholesOptionPricingModelMember
Fair Value, Measurements, Recurring [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Fair value	$ 739	$ 3,406
Expected Volatility [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Estimated fair value assumptions	75	75
Risk-Free Interest Rates [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Estimated fair value assumptions	2.91	2.09
Remaining Contractual Term [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Remaining contractual term	3 years 6 months	4 years 3 months

Comprehensive Loss - Additional

Comprehensive Loss - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Comprehensive Income Net Of Tax [Abstract]
Total comprehensive loss	$ 13,256,000	$ 8,987,000	$ 38,425,000	$ 26,005,000
Tax effect of other comprehensive loss			$ 0	$ 3,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	9 Months Ended
	Jun. 30, 2018Installmentshares	Jan. 31, 2018shares	Dec. 31, 2017shares	Dec. 31, 2016shares	Mar. 31, 2018shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / shares	May 09, 2018shares	Jun. 30, 2015shares	Oct. 31, 2013shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercisable period						10 years
Stock options vest period						4 years
Weighted average grant-date fair value of the options awarded to employees | $ / shares						$ 6.13	$ 5.39
Stock-based compensation | $						$ 5,250	$ 4,265
Aggregate intrinsic value of vested options | $						2,606
Aggregate intrinsic value of unvested options | $						$ 194
Stock Options Granted Outside Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options, Granted						980,000
Time-based RSUs Granted Outside Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units granted						47,000
Performance-based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units granted					240,224
Unrecognized compensation expense related to unvested performance RSUs, expected to vest | $						$ 2,588
Time Based Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period		4 years
Number of restricted stock units granted	444,418	242,396
Stock options vest, number of installments | Installment	2
Unrecognized compensation expense related to unvested options, weighted average period						2 years
Time Based Restricted Stock [Member] | Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period	9 months
Time Based Restricted Stock [Member] | Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period	18 months
Stock Options And Time-based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to unvested options and time-based RSUs, expected to vest | $						$ 13,479
2008 Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock appreciation rights issued in period						0
Additional number of shares authorized for grant						444,000
Shares available for future grants						174
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant										600,000
A&R Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant								7,036,737	2,000,000
Percentage of outstanding common stock			5.00%	5.00%
Increase in share per "Evergreen" provision			956,341	619,181
Shares available for future grants						2,736,552

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of expected option life		6 years
Expected volatility		84.71%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of expected option life	5 years 6 months
Expected volatility	73.26%
Risk-free interest rate	2.32%	1.87%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of expected option life	6 years
Expected volatility	82.00%
Risk-free interest rate	2.98%	2.17%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of shares, beginning balance	3,594,875
Number of shares, Granted	840,461
Number of shares, Exercised	(179,562)
Number of shares, Expired/forfeited/cancelled	(283,237)
Number of shares, ending balance	3,972,537	3,594,875
Number of shares, Vested	2,389,525
Number of shares, Vested and expected to vest	3,972,537
Weighted average exercise price, beginning balance	$ 7.17
Weighted average exercise price, Granted	9.24
Weighted average exercise price, Exercised	5.89
Weighted average exercise price, Expired/forfeited/cancelled	9.25
Weighted average exercise price, ending balance	7.52	$ 7.17
Weighted average exercise price, Vested	7.02
Weighted average exercise price, Vested and expected to vest	$ 7.52
Weighted average remaining contractual life	7 years	7 years 1 month 6 days
Weighted average remaining contractual life, Vested	6 years
Weighted average remaining contractual life, Vested and expected to vest	7 years

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2018shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, beginning balance	270,593
Number of shares, Granted	993,319
Number of shares, Vested and settled	(133,268)
Number of shares, Expired/forfeited/cancelled	(45,416)
Number of shares, ending balance	1,085,228
Number of shares, Expected to vest	852,454

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018USD ($)Segment
Segment Reporting Information [Line Items]
Number of business segments | Segment	2
Acute Care [Member]
Segment Reporting Information [Line Items]
Revenue | $	$ 0

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 18,283	$ 17,114	$ 59,564	$ 52,790
Operating income (loss)	(13,554)	(10,703)	(39,748)	(27,436)
Depreciation and amortization	1,967	1,877	5,757	5,592
Capital expenditures	1,432	1,401	4,363	4,586
Total assets	175,649		175,649		$ 186,226
CDMO [Member]
Segment Reporting Information [Line Items]
Revenue	18,283	17,114	59,564	52,790
Operating income (loss)	6,944	7,781	20,799	18,039
Depreciation and amortization	1,806	1,854	5,484	5,556
Capital expenditures	1,092	1,036	2,245	3,932
Total assets	85,758		85,758		78,136
Acute Care [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	(20,498)	(18,484)	(60,547)	(45,475)
Depreciation and amortization	161	23	273	36
Capital expenditures	340	$ 365	2,118	$ 654
Total assets	$ 89,891		$ 89,891		$ 108,090

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit	$ (146,956)		$ (111,348)
Contract asset	7,465	$ 3,755
Contract asset, increase in estimates arising from changes in transaction price	817
ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Contract asset		3,755
ASU 2014-09 [Member] | Adoption of ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit	5,526	(2,818)
Contract asset	$ 7,465	$ 3,755

Revenue Recognition - Cumulativ

Revenue Recognition - Cumulative Effect Of Changes Made to Consolidated Balance Sheet for Adoption of ASU (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Contract asset	$ 7,465	$ 3,755
Deferred income taxes	25,066		$ 18,573
Total shareholders' equity	13,547		$ 28,848
ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Contract asset		3,755
Deferred income taxes		17,636
Total shareholders' equity		31,666
Adoption of ASU 2014-09 [Member] | ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Contract asset	7,465	3,755
Deferred income taxes	(1,939)	(937)
Total shareholders' equity	$ 5,526	$ 2,818

Revenue Recognition - Impact of

Revenue Recognition - Impact of Adoption of ASU on Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 18,283	$ 17,114	$ 59,564	$ 52,790
Income tax benefit	2,370	2,821	7,430	4,780
Net loss	(13,256)	$ (9,055)	(38,426)	$ (25,997)
Contract asset	7,465		7,465		$ 3,755
Deferred income taxes	25,066		25,066			$ 18,573
Total assets	175,649		175,649			186,226
Accumulated deficit	(146,956)		(146,956)			(111,348)
Total shareholders' equity	13,547		13,547			28,848
Total liabilities and shareholders' equity	175,649		175,649			$ 186,226
ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Contract asset					3,755
Deferred income taxes					17,636
Total shareholders' equity					31,666
Previous Revenue Standard [Member] | ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	17,684		55,854
Income tax benefit	2,532		8,432
Net loss	(13,693)		(41,134)
Deferred income taxes	27,005		27,005
Total assets	170,123		170,123
Accumulated deficit	(152,482)		(152,482)
Total shareholders' equity	8,021		8,021
Total liabilities and shareholders' equity	170,123		170,123
Adoption of ASU 2014-09 [Member] | ASU 2014-09 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	599		3,710
Income tax benefit	(162)		(1,002)
Net loss	437		2,708
Contract asset	7,465		7,465		3,755
Deferred income taxes	(1,939)		(1,939)		(937)
Total assets	5,526		5,526
Accumulated deficit	5,526		5,526		(2,818)
Total shareholders' equity	5,526		5,526		$ 2,818
Total liabilities and shareholders' equity	$ 5,526		$ 5,526

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Changes in Contract Assets (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Jan. 01, 2018
Revenue From Contract With Customer [Abstract]
Contract asset	$ 7,465	$ 3,755
Change in estimate arising from changes in transaction price	817
Reclassification of contract asset to receivables, as the result of rights to consideration becoming unconditional	(4,572)
Contract assets recognized	$ 7,465

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue by Business Segment and Timing of Revenue Recognition (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation Of Revenue [Line Items]
Revenue	$ 18,283	$ 17,114	$ 59,564	$ 52,790
Point In Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	18,086		58,876
Overtime [Member]
Disaggregation Of Revenue [Line Items]
Revenue	197		688
CDMO [Member]
Disaggregation Of Revenue [Line Items]
Revenue	18,283	$ 17,114	59,564	$ 52,790
CDMO [Member] | Point In Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	18,086		58,876
CDMO [Member] | Overtime [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 197		$ 688

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Irish Subsidiary [Member] - Managing Director [Member] - HiTech Health [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Related Party Transaction [Line Items]
Related party transaction expenses	$ 25	$ 278
Service agreement date		2017-11

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Compensation And Retirement Disclosure [Abstract]
Percentage of company's matching contribution with respect to each participant's contribution			100.00%
Company matching contributions to maximum employees eligible compensation			5.00%
Total company contributions to 401 (k) plan	$ 258	$ 208	$ 959	$ 759